PDCD1 and cancer: Although our results might appear to contradict these findings, there is a possibility that if we continued to treat LLC-sh21 tumors with anti–PD-1 therapy, they might eventually develop resistance through selective pressure on cancer cells to adapt against immune attack, chronic T cell exhaustion, or skewing of immune cells to more immunosuppressive phenotypes (Alspach et al, 2019).